Inaddition, a recent study has demonstrated that inhibiting NFκ-B activity, usingthe proteasome inhibitor bortezomib, reduced melanoma cell growth in vitro [9].Although these targets seem to be attractive ones for melanoma therapy in thefuture, most of the findings in this area do not give a comprehensive picturewhich would warrant a review. Here, NFKB1 is linked to melanoma.